Table 2 Iron blood tests and hemoglobin at different time points in the two study groups.
Transferrin saturation (%) | Ferritin (ng/ml) | Hemoglobin (mg/dl) | Erythropoietin therapy n (%) | |
---|---|---|---|---|
Group 1 (FCM therapy) | ||||
Baseline (n = 239) | 19.4 ± 9 | 103 ± 83 | 9.7 ± 1.5 | 132 (55%) |
12-months follow-up (n = 212) | 29.9 ± 12 | 275 ± 151 | 11.9 ± 1.8 | 110 (52%) |
p < 0.05 | p < 0.05 | p < 0.05 | p = 0.8 | |
Baseline (n = 239) | 19.4 ± 9 | 103 ± 83 | 9.7 ± 1.5 | 132 (55%) |
18-months follow-up (n = 193) | 31.0 ± 17 | 310 ± 193 | 11.9 ± 1.9 | 89 (46%) |
p < 0.05 | p < 0.01 | p < 0.05 | p = 0.3 | |
Group 2 (ferrous sulfate therapy) | ||||
Baseline (n = 110) | 19.8 ± 8 | 102 ± 112 | 9.8 ± 1.6 | 62 (56%) |
12-months follow-up (n = 96) | 22.0 ± 11 | 180 ± 132 | 10.1 ± 1.8 | 60 (62%) |
p = 0.1 | p = 0.1 | p = 0.4 | p = 0.6 | |
Baseline (n = 110) | 19.8 ± 8 | 102 ± 112 | 9.8 ± 1.6 | 62 (56%) |
18-months follow-up (n = 87) | 24.0 ± 12 | 175 ± 145 | 9.9 ± 1.7 | 56 (64%) |
p = 0.4 | p = 0.1 | p = 0.7 | p = 0.4 |